Critical care hepatology: definitions, incidence, prognosis and role of liver failure in critically ill patients
- PMID: 36163253
- PMCID: PMC9511746
- DOI: 10.1186/s13054-022-04163-1
Critical care hepatology: definitions, incidence, prognosis and role of liver failure in critically ill patients
Abstract
Organ dysfunction or overt failure is a commonplace event in the critically ill affecting up to 70% of patients during their stay in the ICU. The outcome depends on the resolution of impaired organ function, while a domino-like deterioration of organs other than the primarily affected ones paves the way for increased mortality. "Acute Liver Failure" was defined in the 1970s as a rare and potentially reversible severe liver injury in the absence of prior liver disease with hepatic encephalopathy occurring within 8 weeks. Dysfunction of the liver in general reflects a critical event in "Multiple Organ Dysfunction Syndrome" due to immunologic, regulatory and metabolic functions of liver parenchymal and non-parenchymal cells. Dysregulation of the inflammatory response, persistent microcirculatory (hypoxic) impairment or drug-induced liver injury are leading problems that result in "secondary liver failure," i.e., acquired liver injury without underlying liver disease or deterioration of preexisting (chronic) liver disease ("Acute-on-Chronic Liver Failure"). Conventional laboratory markers, such as transaminases or bilirubin, are limited to provide insight into the complex facets of metabolic and immunologic liver dysfunction. Furthermore, inhomogeneous definitions of these entities lead to widely ranging estimates of incidence. In the present work, we review the different definitions to improve the understanding of liver dysfunction as a perpetrator (and therapeutic target) of multiple organ dysfunction syndrome in critical care.
Keywords: Acute liver failure; Acute-on-chronic liver failure; Intensive care unit; Multiple organ failure; Secondary liver failure.
© 2022. The Author(s).
Conflict of interest statement
Aritz Perez Ruiz de Garibay is affiliated with ADVITOS, GmbH, a company that offers extracorporeal support devices including liver support. No statements regarding the use of devices for liver support are made in this review. None of the other authors reports a link with ADVITOS or any other link to commercial entities that would be perceived as conflict of interest.
Figures
References
-
- Mochida S, Nakayama N, Matsui A, Nagoshi S, Fujiwara K. Re-evaluation of the Guideline published by the Acute Liver Failure Study Group of Japan in 1996 to determine the indications of liver transplantation in patients with fulminant hepatitis. Hepatol Res. 2008;38:970–979. doi: 10.1111/j.1872-034X.2008.00368.x. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
